We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Johnson & Johnson (JNJ - Free Report) was down 1.25% at $252.83. This change lagged the S&P 500's daily gain of 0.66%. Meanwhile, the Dow gained 0.18%, and the Nasdaq, a tech-heavy index, added 1.05%.
The world's biggest maker of health care products's stock has dropped by 6.98% in the past month, falling short of the Medical sector's loss of 3.74% and the S&P 500's gain of 0.55%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on October 13, 2026. The company's earnings per share (EPS) are projected to be $2.9, reflecting a 3.57% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $25.37 billion, up 5.75% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $11.54 per share and revenue of $101.15 billion, which would represent changes of +6.95% and +7.39%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.61% downward. As of now, Johnson & Johnson holds a Zacks Rank of #3 (Hold).
Looking at its valuation, Johnson & Johnson is holding a Forward P/E ratio of 22.19. This expresses a premium compared to the average Forward P/E of 15.91 of its industry.
We can also see that JNJ currently has a PEG ratio of 2.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.91.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 109, this industry ranks in the top 45% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Johnson & Johnson (JNJ - Free Report) was down 1.25% at $252.83. This change lagged the S&P 500's daily gain of 0.66%. Meanwhile, the Dow gained 0.18%, and the Nasdaq, a tech-heavy index, added 1.05%.
The world's biggest maker of health care products's stock has dropped by 6.98% in the past month, falling short of the Medical sector's loss of 3.74% and the S&P 500's gain of 0.55%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on October 13, 2026. The company's earnings per share (EPS) are projected to be $2.9, reflecting a 3.57% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $25.37 billion, up 5.75% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $11.54 per share and revenue of $101.15 billion, which would represent changes of +6.95% and +7.39%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.61% downward. As of now, Johnson & Johnson holds a Zacks Rank of #3 (Hold).
Looking at its valuation, Johnson & Johnson is holding a Forward P/E ratio of 22.19. This expresses a premium compared to the average Forward P/E of 15.91 of its industry.
We can also see that JNJ currently has a PEG ratio of 2.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.91.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 109, this industry ranks in the top 45% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.